HiTech Health awarded with €7m government funding for ‘disruptive’ project
HiTech Health and our partners, Relevium Medical and Professor Garry Duffy’s Laboratory at NUI Galway are honoured to receive €7 million from the Disruptive Technologies Innovation Fund (DTIF), administered by Enterprise Ireland. This award will support the development of a novel treatment for Knee Osteoarthritis with the potential to regenerate the damaged knee joint whilst providing long-lasting pain relief.
Dr Brian Harrison, MD Hi-Tech Health, “We are excited to work with Relevium and Prof Garry Duffy’s team on the process development, scale up and GMP manufacturing of this novel therapeutic candidate at our Galway facilities. With all parties in the local area, we believe this will strengthen our partnership and help with developing this novel Knee Osteoarthritis therapy.”
Dr Alison Liddy, Founder and CEO Relevium, “This funding will enable Relevium and our partners to develop this ground-breaking treatment that has the potential to transform the lives of people living with Knee Osteoarthritis.”
Professor Garry Duffy, NUI Galway, “My team at NUI Galway are delighted to be part of this project and to work with industrial leaders to develop an impactful solution for Osteoarthritis.”
Read the full Irish Times article here: Government to provide €95m in funding for ‘disruptive’ projects
Find out more about Relevium: www.relevium-medical.com
Find out more about NUI Galway: www.nuigalway.ie/medicine-nursing-and-health-sciences/
Recent News
ATMP Sector Spotlight: H1 2025 Review
The HiTech Health team has reviewed recent developments in the Advanced Therapeutic Medicinal Product (ATMP) sector during the first half of 2025. Below are some key updates from the industry so far: Sector Summary: In Europe, the ATMP sector is on track to...
Developing an Investigational Medicinal Product (IMP)? Considering conducting clinical trials in the UK?
The global clinical trials market is expected to nearly double to over £80 billion by 2032 and the United Kingdom remains one of the world’s leading destinations for conducting clinical research. Notably, the UK accounts for approximately 9.5% of all global cell and...
CanVas Consortium including HiTech Health receives €10.7 million DTIF grant to advance new class of cell therapy to clinic for early brain injury
Dublin, Ireland, 10th April 2025 – HiTech Health, a Contract Development and Manufacturing Organisation (CDMO) specialising in advanced medicines, is delighted to communicate that the CanVas consortium led by HAON life sciences (a leading cell therapy biotech company)...
Stay Up To Date
Connect with us to receive the latest HiTech Health and industry updates.